Nektar Therapeutics (NKTR) on Monday reported positive results from a 16-week treatment extension in its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe Alopecia Areata. The company's shares rose more than 17% in pre-market trading.
In the REZOLVE-AA study, during the initial 36-week induction phase, participants were randomized to receive either two dose levels of rezpegaldesleukin or placebo. Patients who completed the induction phase and had a Severity of Alopecia Tool (SALT) score above 20 at week 36, along with evidence of hair regrowth, were eligible to continue treatment at their assigned dose in a 16-week extension period through week 52.
The study showed continued improvement in hair regrowth through week 52. Between weeks 36 and 52, 29% of patients on the low dose and 31% on the high dose achieved a SALT score of 20 or below, compared with none in the placebo group. A SALT score less than or equal to 20 indicates at least 80% scalp hair coverage.
Nektar said the treatment continued to demonstrate a favorable safety and tolerability profile over 52 weeks, consistent with earlier data.
The company added that the results support advancing rezpegaldesleukin into late-stage development for alopecia areata.
Nektar stock had closed at $84.86 on Friday, up 1.04%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.